Q

Qualigen Therapeutics
D

QLGN

3.70000
USD
-0.40
(-9.76%)
Market Open
Volume
2,977
EPS
0
Div Yield
0
P/E
-2
Market Cap
99,981,544
OverviewSignalsIdeasNews
Related Instruments
    A
    AHCO
    -0.280
    (-2.46%)
    11.100 USD
    A
    APLT
    -0.29000
    (-4.87%)
    5.66000 USD
    A
    ARDX
    -0.02500
    (-0.45%)
    5.52500 USD
    C
    CTIC
    0.11000
    (2.54%)
    4.44000 USD
    L
    LPX
    -1.430
    (-1.46%)
    96.730 USD
    M
    MTEM
    0.00200
    (0.14%)
    1.45600 USD
    S
    SLDB
    -0.24000
    (-2.68%)
    8.70000 USD
    V
    VYGR
    -0.59000
    (-6.37%)
    8.67000 USD
    More
News

Title: Qualigen Therapeutics Inc

Sector: Healthcare
Industry: Biotechnology
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.